EE324 Cost-Effectiveness analysis of Atezolizumab as Adjuvant Treatment of Patients With Stage II-IIIA Non-Small Cell Lung Cancer, With Pd-L1≥50% of Tumor Cells, in France
| Autor: | Plessala, I, Chouaid, C, Souquet, PJ, Cawston, H, Cortes, J, Le Lay, K, Roula, A |
|---|---|
| Zdroj: | In Value in Health December 2022 25(12) Supplement:S117-S118 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect